207 related articles for article (PubMed ID: 38540782)
1. High-throughput enrichment of portal venous circulating tumor cells for highly sensitive diagnosis of CA19-9-negative pancreatic cancer patients using inertial microfluidics.
Zhu Z; Zhang Y; Zhang W; Tang D; Zhang S; Wang L; Zou X; Ni Z; Zhang S; Lv Y; Xiang N
Biosens Bioelectron; 2024 May; 259():116411. PubMed ID: 38781696
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer from bench to bedside: molecular pathways and treatment options.
Kosmidis C; Sapalidis K; Kotidis E; Mixalopoulos N; Zarogoulidis P; Tsavlis D; Baka S; Man YG; Kanellos J
Ann Transl Med; 2016 May; 4(9):165. PubMed ID: 27275478
[TBL] [Abstract][Full Text] [Related]
3. A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present.
Bestari MB; Joewono IR; Syam AF
Biomolecules; 2024 Mar; 14(3):. PubMed ID: 38540782
[TBL] [Abstract][Full Text] [Related]
4. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review.
Yang J; Xu R; Wang C; Qiu J; Ren B; You L
Cancer Commun (Lond); 2021 Dec; 41(12):1257-1274. PubMed ID: 34331845
[TBL] [Abstract][Full Text] [Related]
5. Circulating MicroRNAs as Noninvasive Diagnostic and Prognostic Biomarkers in Pancreatic Cancer: A Review.
Khan IA; Saraya A
J Gastrointest Cancer; 2023 Sep; 54(3):720-730. PubMed ID: 36322366
[TBL] [Abstract][Full Text] [Related]
6. New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer.
Yuan W; Tang W; Xie Y; Wang S; Chen Y; Qi J; Qiao Y; Ma J
Oncotarget; 2016 Nov; 7(48):80033-80045. PubMed ID: 27713117
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of various liquid biopsy methods for pancreatic cancer: A systematic review and meta-analysis.
Zhu Y; Zhang H; Chen N; Hao J; Jin H; Ma X
Medicine (Baltimore); 2020 Jan; 99(3):e18581. PubMed ID: 32011436
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.
Takai E; Yachida S
World J Gastroenterol; 2016 Oct; 22(38):8480-8488. PubMed ID: 27784960
[TBL] [Abstract][Full Text] [Related]
9. Unexplained increases in serum carcinoembryonic antigen levels in colorectal cancer patients during the postoperative follow-up period: an analysis of its incidence and longitudinal pattern.
Nozawa H; Yokota Y; Emoto S; Yokoyama Y; Sasaki K; Murono K; Abe S; Sonoda H; Shinagawa T; Ishihara S
Ann Med; 2023; 55(2):2246997. PubMed ID: 37963211
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Conroy T; Pfeiffer P; Vilgrain V; Lamarca A; Seufferlein T; O'Reilly EM; Hackert T; Golan T; Prager G; Haustermans K; Vogel A; Ducreux M;
Ann Oncol; 2023 Nov; 34(11):987-1002. PubMed ID: 37678671
[No Abstract] [Full Text] [Related]
11. Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need.
Liou GY; Byrd CJ
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173913
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic Cancer Biomarkers: Oncogenic Mutations, Tissue and Liquid Biopsies, and Radiomics-A Review.
Amaral MJ; Oliveira RC; Donato P; Tralhão JG
Dig Dis Sci; 2023 Jul; 68(7):2811-2823. PubMed ID: 36988759
[TBL] [Abstract][Full Text] [Related]
13. Can combined use of tumor markers in pancreatic cancer be a solution to short- and long-term consequences?: A retrospective study.
Esen E; Aslan M; Morkavuk SB; Azili C; Ersoz S; Bahcecioglu IB; Unal AE
Medicine (Baltimore); 2023 Mar; 102(11):e33325. PubMed ID: 36930073
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
